Live feed08:00:00·3dPRReleasevia QuantisnowTakeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment ExpectationsByQuantisnow·Wall Street's wire, on your screen.TAK· Takeda Pharmaceutical Company LimitedHealth Care
